Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Interventional Neuroradiology's Growing Pains

This article was originally published in Start Up

Executive Summary

Neuroendovascular devices for treating hemorrhagic and ischemic stroke, while investigational, are gaining attention because of technology advances, intriguing anecdotal evidence of efficacy in a field in which previous drug therapies haven't worked, and positive but controversial emerging clinical data. Companies are pursuing neuro applications of endovascular devices, but despite lots of noise, clinical challenges and uncertain market potential restrain many from investing heavily in the field.

You may also be interested in...



ev3: The Virtues of Focus

Six years ago, ev3 was launched aiming at a broad attach on cardio- and endovascular disease. But the company found including coronary devices in its mix too difficult and too costly. Instead, the company shifted directions three years ago, with a focus on peripheral and neurovascular disease. In the process, it hopes to address what it calls "the innovation gap," the lack of devices developed specifically for the PVD and neurovascular specialists.

Where are They Now? Yesterday's Stroke Companies

In May 2000, START-UP profiled five medical device companies targeting stroke, in an article entitled "Making Progress in Stroke." We recently revisited Radiant Medical, Medivance, MicroVention, and two others to find out what went according to plan and what didn't In 2007, we have to say that there has in fact not been much progress, at least in acute ischemic stroke. Two companies dropped out, two remain active with promising programs--in clinical areas other than stroke, and one, which avoided ischemic stroke in the first place, enjoyed a nice exit.

Concentric Medical: Breaking the Stroke Device Barrier

Concentric overcame major technology and regulatory challenges to be first to market in a large, complex device space, treating acute ischemic stroke, which has befuddled big companies and start-ups.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT037264

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel